Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
2018 · New England Journal of Medicine · 3,376 citations
https://doi.org/10.1056/nejmoa1801174
S
Shaun G. Goodman
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
801
Papers
45.1K
Citations
101
h-index
380
i10-index
Shaun G. Goodman is an academic researcher from St. Michael's Hospital. The author has contributed to research in topics: Acute Myocardial Infarction Research & Antiplatelet Therapy and Cardiovascular Diseases & Atrial Fibrillation Management and Outcomes. The author has an h-index of 101, co-authored 681 publications.
ORCID: 0000-0001-8068-2440Papers by this author
worksInitial Invasive or Conservative Strategy for Stable Coronary Disease
2020 · New England Journal of Medicine · 2,321 citations
https://doi.org/10.1056/nejmoa1915922
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
2018 · The Lancet · 1,728 citations
https://doi.org/10.1016/s0140-6736(18)32261-x
Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)
2006 · BMJ · 1,607 citations
https://doi.org/10.1136/bmj.38985.646481.55
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
2020 · Journal of the American College of Cardiology · 545 citations
https://doi.org/10.1016/j.jacc.2019.10.057
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
2014 · American Heart Journal · 409 citations
https://doi.org/10.1016/j.ahj.2014.07.028
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat